Results 141 to 150 of about 23,127 (334)

ChREBP drives β‐cell proliferation under metabolic stress but not in pregnancy‐induced β‐cell expansion

Journal of Diabetes Investigation, EarlyView.
ChREBP is a context‐dependent regulator of adaptive β‐cell proliferation. It plays a pivotal role in driving β‐cell expansion under pathophysiological metabolic stress, such as insulin resistance and hyperglycemia, but has a limited role during physiological expansion in pregnancy.
Sodai Kubota, Seiya Banno, Katsumi Iizuka, Hiromi Tsuchida, Saki Kubota‐Okamoto, Teruaki Sakurai, Yoshihiro Takahashi, Toshinori Imaizumi, Takehiro Kato, Yukio Horikawa, Shin Tsunekawa, Ryota Usui, Hisato Tatsuoka, Shinsuke Tokumoto, Takaaki Murakami, Yuuka Fujiwara, Hitoshi Kuwata, Yuji Yamazaki, Yuichiro Yamada, Yutaka Seino, Daisuke Yabe   +20 more
wiley   +1 more source

Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells

eLife
G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and
Affiong Ika Oqua, Kin Chao, Liliane El Eid, Lisa Casteller, Billy P Baxter, Alba Miguéns-Gómez, Sebastian Barg, Ben Jones, Jorge Bernardino de la Serna, Sarah L Rouse, Alejandra Tomas   +10 more
doaj   +1 more source

Biology of incretins: GLP-1 and GIP.

Gastroenterology, 2007
L. Baggio, D. Drucker
semanticscholar   +1 more source

Diabetes and menopause: A critical yet neglected intersection

Diabetic Medicine, EarlyView.
Isabell Haage, David Studer, Petra Stute, Lia Bally   +3 more
wiley   +1 more source

Recent advances in incretin biology and therapeutics: From glucose‐dependent insulinotropic polypeptide reappraisal to next‐generation agonists

Journal of Diabetes Investigation, EarlyView.
Future directions in incretin research: Three major directions currently shape therapeutic innovation in incretin research: multi‐receptor agonism, oral drug development, and mechanistic reappraisal of glucose‐dependent insulinotropic polypeptide (GIP) physiology.
Sodai Kubota, Yutaka Seino, Daisuke Yabe
wiley   +1 more source

Five‐year follow‐up of incretin‐based therapy in a patient with KCNJ11‐related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction

Journal of Diabetes Investigation, EarlyView.
In a woman with KCNJ11‐related permanent neonatal diabetes mellitus, incretin‐based therapy enabled insulin discontinuation and maintained glycemic control for more than 5 years, with HbA1c between 6.1% and 6.5% on the lowest semaglutide dose, dose‐dependent improvement in insulin secretion, and an approximately 60% reduction in glibenclamide dose ...
Toshiaki Ohkuma, Ryoichiro Aotani, Wakako Sakamoto, Ayaka Oshiro, Tetsuro Ago   +4 more
wiley   +1 more source

Advantages of incretin-based treatment in management of type 2 diabetes [PDF]

, 2017
The risk of hypoglycemia with sulfonylureas is higher in the presence of diabetic nephropathy. Selective DPP-4 inhibitors lead to physiologic increases in the incretins GLP-1 and gastric inhibitory polypeptide and preferable for the management of ...
Abbas, Ahmad L., Fadieieva, Hanna Anatoliivna, Фадеева, Анна Анатольевна, Фадєєва, Ганна Анатоліївна   +3 more
core  

Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review

Obesity Reviews, EarlyView.
ABSTRACT Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling.
Ana Raimunda Dâmaso, Flávia Campos Corgosinho, Deborah Cristina Landi Masquio, Nayra Figueiredo, Fabiana Kattah, Cintia Cercato, Lian Tock, Raquel Munhoz da Silveira Campos   +7 more
wiley   +1 more source

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, EarlyView.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source

Incretin Concepts [PDF]

Diabetes Care, 2010
openaire   +2 more sources